- Bumetanide
drugbox
IUPAC_name = 3-butylamino-4-phenoxy-5-sulfamoyl-benzoic acid
width = 156
CAS_number = 28395-03-1
ChemSpiderID = 2377
ATC_prefix = C03
ATC_suffix = CA02
ATC_supplemental =
PubChem = 2471
DrugBank = APRD00294
smiles = CCCCNc1cc(cc(c1Oc2ccccc2)S(N)(=O)=O)C(O)=O
C = 17 | H = 20 | N = 2 | O = 5 | S = 1
molecular_weight = 364.417 g/mol
bioavailability = almost complete
protein_bound = 97%
metabolism = hepatic
elimination_half-life = 60-90 minutes
pregnancy_AU = B3
pregnancy_US = C
legal_AU = S4
legal_UK = POM
legal_US = Rx-only
routes_of_administration = oral
excretion = renal Bumetanide is aloop diuretic of the sulfamyl category to treatheart failure . It is often used in patients in whom high doses offurosemide are ineffective. It is marketed byHoffmann-La Roche with the brand name Bumex. The main difference between the two substances is inbioavailability . Furosemide is incompletely absorbed in the intestine (40%), and there is substantial inter- and intraindividual differences in bioavailability (range 10-90%). Bumetanide is completely absorbed (80%), and the absorption is not altered when it is taken with food. It is said to be a more predictable diuretic, meaning that the predictable absorption is reflected in a more predictable effect.Bumetanide is 40 times more potent than furosemide (for patients with normal
renal function ).External links
* [http://www.rocheusa.com/products/bumex/pi.pdf Bumex] (manufacturer's website)
* [http://www.meds-help.com/bumetanide/ Bumetanide] (patient information)
Wikimedia Foundation. 2010.